Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma

About one third of cancers harbor activating mutations in rat sarcoma viral oncogene homolog (RAS) oncogenes. In melanoma, aberrant neuroblastoma-RAS (NRAS) signaling fuels tumor progression in about 20% of patients. Current therapeutics for NRAS driven malignancies barely impact overall survival. T...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Invest Dermatol
Auteurs principaux: Posch, C, Cholewa, BD, Vujic, I, Sanlorenzo, M, Ma, J, Kim, ST, Kleffel, S, Schatton, T, Rappersberger, K, Gutteridge, R, Ahmad, N, Ortiz/Urda, S
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4567913/
https://ncbi.nlm.nih.gov/pubmed/26016894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/jid.2015.198
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires